AstraZeneca Pharma India share news and announcements
NSE: ASTRAZENBSE: 506820Pharmaceuticals & BiotechnologySmall Cap
Formerly Astra IDL
Last close ₹5,988.50down ₹112.50 (1.84%)BSE ₹5,988.15
Share price at the NSE close on 23 Oct 2026. Previous close ₹6,101.00.
52-week range of traded prices to 23 Oct 2026
₹5,640.00Low, 9 Oct 2026₹9,849.50High, 3 Nov 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹14,971 Cr333rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 11 Aug 2026
- 88.3
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 26 May 2026
- 17.2
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.60%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 11 Aug 2026
- 20.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 11 Aug 2026
- 24.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 26 May 2026
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 7,11847.8% delivered
AstraZeneca Pharma India board and management
40 filed, newest first.
Sep 2026
15 Sep · Management
Jul 2026
22 Jul · Management
Jun 2026
13 Jun · Management
Jun 2025
May 2024
Feb 2024
8 Feb · Management
Dec 2023
Nov 2023
Jul 2023
31 Jul · Management
May 2023
Dec 2022
Nov 2022
Aug 2022
Dec 2021
Aug 2021
Aug 2020
12 Aug · Management
May 2020
19 May · Management
Nov 2019
12 Nov · Management
Aug 2019
8 Aug · Management
Mar 2019
Feb 2019
May 2017
Nov 2016
Jan 2016
Nov 2014
24 Nov · Management
Mr. Robert Haxton has resigned as the Wholetime Director of the Company. The Board has accepted the resignation of Mr. Haxton and that he would be relieved from the said position, effective December 14, 2014.3 Nov · Management
Board appointed Ms. Rebekah Martin as an Additional Director of the Company, effective November 03, 2014.
Aug 2014
1 Aug · Management
Mr. Pawan Singhal has resigned from the services of the Company and has accordingly ceased to be its Company Secretary and Compliance Officer, effective July 31,2014.
Nov 2011
Sep 2011
Jun 2011
10 Jun · Management
Board of the Directors of the Company at its meeting held on May 13, 2011 has noted the appointment of Mr. Himanshu Agarwal as the CFO of the Company, with effect from May 03, 2011. The same has been approved by the Audit Committee of the Board of Directors in its meeting held on February 22, 2011.
Oct 2010
Apr 2010
26 Apr · Management
Board of Directors of the Company at its meeting held on April 26, 2010 has noted the appointment of Ms. Anita Zutshi as the Chief Financial Officer of the Company w.e.f. April 03, 2010.
Feb 2009
19 Feb · Management
Vide its letter dated February 18, 2009 that: Mr. Francis McNamara has been appointed as a Director on the Board of Directors of the Company w.e.f. February 18, 2009 in the Casual Vacancy arising out of the resignation of Mr. Graham Baker who had resigned from the Board w.e.f. December 31, 2008. The updated list of the Board of Directors of the Company as on date are as follows: (1) Mr. D E Udwadia, Chairman; (2) Mr. K S Shah, Director; (3) Mr. Ian MD Brimicombe, Director; (4) Mr. Bhasker V Iyer, Director; (5) Mr. Francis McNamara, Director; (6) Mr. Anandh Balasundaram, Managing Director.
Dec 2008
31 Dec · Management
Mr. Graham Baker has resigned as a Director of the Company with effect from December 31, 2008. Further the Company has submitted a copy of updated list of Board of Directors of the Company as on December 31, 2008: 1) Mr. D.E. Udwadia - Chairman & Independent Director, 2) Mr. K.S. Shah - Independent Director, 3) Mr. Ian MD Brimicombe - Director, 4) Mr. Bhasker V. Iyer - Director, 5) Mr. Anandh Balasundaram - Managing Director.
May 2007
21 May · Management
At a Meeting of the Board of Directors held today i.e. May 21, 2007, the board has noted/approved the following: a) Consequent to the transfer of Mr Bhasker V Iyer, Managing Director, to a regional role in AstraZeneca as the Area vice President- South East Asia and India, with effect from June 1, 2007, he would be stepping down as Managing Director of the Company from end of the business hours on May 31, 2007 and further in terms of his appointment, Mr Bhaskar V. Iyer would ipso facto cease to be a Director of the Company from that date; b)Appointment of Mr Anandh Balasundaram as an Additional Director of the Company, with effect from June 1, 2007 ; and c) Appointment of Mr Anandh Balasundaram as the Managing Director of the Company in the place of Mr. Bhaskar V. Iyer, with effect from June 1, 2007, for a period of five years, subject to approval of the Shareholders of the Company at the next General Meeting of the Company
Mar 2007
12 Mar · Management
At the Meeting of the Board of Directors held today i.e., 23.02.2007 (afternoon), Mr Ruud Dobber has been appointed as a Director of the Company
Jan 2007
9 Jan · Management
Mr. Andrew Howden has resigned as Director from the Board of the Company, effective from the close of 27th November, 20064 Jan · Management
Mr. N. R. Srinivasan who has joined the Company as Vice President - Legal & Company Secretary in December 2006 shall be the Compliance Officer pursuant to the Listing Agreement. Name of the Compliance Officer: N. R. Srinivasan. Phone: 080-23622021 - 27, Extn.409. Direct: 080-23622034. Fax: 080-23622044. E-mail ID: [email protected]. Registered Office Address: AstraZeneca Pharma India Limited, Off Bellary Road, Hebbal, Bangalore 560 024. Correspondence Address: -do-.